ENSCW · Ensysce Biosciences, Inc.

Summary

Ensysce Biosciences, Inc. received a Nasdaq Deficiency Letter on February 25, 2026, for failing to meet the Minimum Bid Price requirement of $1.00 per share under Listing Rule 5550(a)(2), as the bid price closed below $1.00 for 30 consecutive business days. The Company has 180 calendar days until August 24, 2026, to regain compliance by achieving a $1.00 closing bid price for at least 10 consecutive business days, with no immediate effect on its Nasdaq Capital Market listing under symbol ENSC.

Key takeaways

• Received Deficiency Letter from Nasdaq on February 25, 2026
• Non-compliance with Nasdaq Listing Rule 5550(a)(2) due to bid price below $1.00 for 30 consecutive business days
• 180 calendar days to regain compliance by August 24, 2026
• Must close at $1.00 Minimum Bid Price for minimum 10 consecutive business days
• Possible extension to second 180-day period if other standards met
• Stock continues trading on Nasdaq Capital Market under ENSC